FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a system for producing a protein, a pharmaceutical composition for expression of alphavirus replicase and/or replicon, a method for producing a protein in a cell, an eucaryotic host cell for producing a protein, and a method for producing a protein in a subject. In one of the embodiments, the system contains RNA structure for expression of alphavirus replicase and RNA replicon, which can be replicated by replicase in trains, wherein RNA structure contains 5' UTR, an open reading frame, encoding replicase, and 3' UTR, where RNA structure contains 5’-cap for replicase transmission, and RNA replicon contains 5' replicative sequence of alphavirus recognition, an open reading frame encoding the protein of interest, and 3' replicative sequence of alphavirus recognition.
EFFECT: obtaining trans-replicating RNA for producing a protein.
15 cl, 8 dwg, 7 ex
Title | Year | Author | Number |
---|---|---|---|
RNA REPLICON FOR UNIVERSAL AND EFFECTIVE GENE EXPRESSION | 2017 |
|
RU2748892C2 |
FORMULA FOR INTRODUCING RNA | 2019 |
|
RU2797147C2 |
COMPOSITION FOR RNA ADMINISTRATION | 2017 |
|
RU2746118C2 |
METHOD FOR INCREASING RNA EXPRESSION IN CELL | 2018 |
|
RU2784654C2 |
ANTIGEN DELIVERY PLATFORMS | 2011 |
|
RU2597974C2 |
SEQUENCE 3'-UTR FOR RNA STABILIZATION | 2016 |
|
RU2720934C2 |
3'-UTR SEQUENCES FOR RNA STABILIZATION | 2016 |
|
RU2783165C1 |
EMULSIONS OF “OIL-IN-WATER” TYPE, WHICH CONTAIN NUCLEIC ACIDS | 2012 |
|
RU2606846C2 |
MICROPARTICLES FOR DELIVERY OF HETEROLOGOUS NUCLEIC ACIDS | 2001 |
|
RU2295954C2 |
ADENOVIRUS/ALFAVIRUS HYBRID VECTOR FOR EFFECTIVE ADMINISTRATION AND EXPRESSION OF THERAPEUTIC GENES IN TUMOR CELLS | 2005 |
|
RU2394104C2 |
Authors
Dates
2021-07-29—Published
2017-03-13—Filed